Volume 2, Issue 9
Acknowledgementsp. 949
Acknowledgements: Clinical Investigation (2012) Vol 2: Iss 9
Corrigendump. 952
Corrigendum: Clin Invest (2012); 2(9) 603-614.
News and Viewsp. 859–861
The future of TB treatment: trial shows potential for a new TB drug
Interviewp. 863–865
American Society of Clinical Oncology 2012 annual meeting: new optimism for fighting platinum resistance
Author(s): Maurie Markman
Research Updatep. 867–871
Developing a National Network for Clinical Research: The NIHR Medicines for Children Research Network (MCRN)
Author(s): Gemma L Saint, Vanessa Poustie, Rosalind L Smyth
Review: Clinical Trail Outcomesp. 873–881
Immunotherapy & cancer - making the past prologue Immunotherapeutic combinations for cancer
Author(s): Susan F Slovin
Review: Clinical Trail Outcomesp. 883–893
A therapeutic renaissance: emergence of novel targeted agents for metastatic melanoma
Author(s): C Lance Cowey
Review: Clinical Trail Outcomesp. 895–907
Crizotinib for the treatment of non-small-cell lung cancer with ALK gene rearrangements
Author(s): Muhammad Alamgeer, Toni-Maree Rogers, Stephen B Fox, Benjamin Solomon
Review: Clinical Trail Outcomesp. 909–921
Emerging medical treatments for actinic keratoses, squamous cell carcinoma and basal cell carcinoma
Author(s): Nasreen Ghuznavi, Nadia F Nocera, Andrew R Guajardo, Jeffrey M Weinberg
Review: Clinical Trail Outcomesp. 923–937
HCV protease inhibitors: using the evidence to guide clinical practice
Author(s): Derek Yu, Jordan J Feld
Review: Clinical Trail Outcomesp. 939–948
Telavancin in the treatment of nosocomial pneumonia: review of the clinical evidence
Author(s): Antoni Torres
Erratum
